Key clinical point: Adding ribociclib to fulvestrant in the first or second line improves overall survival of advanced breast cancer in postmenopausal women.

Major finding: Median overall survival was not reached with ribociclib/fulvestrant versus 40 months for fulvestrant/placebo.

Study details: A randomized, phase 3 trial in 726 postmenopausal women with advanced de novo or relapsed breast cancer.

Disclosures: MONALEESA-3 is supported by Novartis. Dr. Slamon disclosed a consulting or advisory role, research funding, honoraria, and travel expenses from Novartis and others. Dr. Loibl disclosed honoraria and research grants from Novartis and others.